

SCEMBLIX - Patient monitoring and management - HCP

[Prescribing information](#)

Image



Image



 **SCEMBLIX[®]** ▼
(asciminib) 20 mg, 40 mg tablets


SCEMBLIX[®] ▼ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.¹

Patient monitoring and management

Regular monitoring is important to assess treatment benefits and inform the decision to switch^{2,3}

Monitoring milestones of BCR-ABL1 transcript levels by the IS (international scale) at 3, 6 and 12 months is essential to determine treatment interventions.^{2,3}

In later lines of treatment, acceptable response cannot be formally defined, but a BCR-ABL^{IS} >1% is insufficient for optimal survival.^{2,3}



Adapted from Hochhaus A, et al. 2020 and Smith G, et al. 2020.^{2,3}

For full details on monitoring, please see the [ELN 2020 Guidelines](#) and the [SCEMBLIX SmPC](#).

Even after MMR is achieved, monitoring of MMR should continue every 3-6 months^{2,3}

Make monitoring and management effective

[Visit our resources pages for patient support tools](#)

BCR-ABL, breakpoint cluster region and Abelson murine leukaemia viral oncogene homologue; CCyR, complete cytogenetic remission; EMR, early molecular response; IS, international scale; MMR, major molecular response; MR, molecular response.

For further information, please refer to the [Summary of Product Characteristics](#).

References:

1. SCEMBLIX (asciminib) Summary of Product Characteristics.
2. Hochhaus A, et al. *Leukemia* 2022;34:996-984.
3. Smith G, et al. *Br J Haematol* 2020;191(2):171-193.

UK | November 2024 | FA-11311678

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/haematology/scemblix/patient-monitoring>